EET-Based Therapeutics Mitigate Sorafenib-Associated Glomerular Cell Damage
MDB-52 appears to counteract gene disruptions and protect against sorafenib-induced kidney damage. Overall, 8,9-EET analogs targeting glomerular cells could be potential therapeutic agents to lessen sorafenib-related nephrotoxicity.
Authors
- Abdul H. Khan (ORCID: https://orcid.org/0000-0001-5940-9300)
- Shobanbabu Bommagani
- Tsigereda Weldemichael (ORCID: https://orcid.org/0000-0002-2410-7051)
- Rawand S. Mohamed
- Abhishek Mishra (ORCID: https://orcid.org/0000-0003-2071-5348)
- Darin E. Jones (ORCID: https://orcid.org/0000-0003-1581-3453)
- John D. Imig (ORCID: https://orcid.org/0000-0002-9668-2899)
- Anders Vik (ORCID: https://orcid.org/0000-0002-7864-3271)
- Donald J. Johann
- Samaneh Goorani (ORCID: https://orcid.org/0000-0003-0342-6966)
- Marcus de Bourg
Institutions
- University of Oslo (NO)
- University of Arkansas for Medical Sciences (US)
Publication Details
- Journal
- Biomolecules
- Published
- 2025-09-16
- DOI
- https://doi.org/10.3390/biom15091324
- Primary Topic
- Eicosanoids and Hypertension Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Arkansas for Medical Sciences